Results: Sixty-five patients completed PEG-IFN -2a therapy. Among them, 17 (26.15%) were found HBeAg seroconversion and 19 (29.23%) were found HBeAg loss at cessation of therapy. None of age, gender, ALT level and HBV DNA load at baseline had relationship with HBeAg seroconversion. HBeAg level of baseline was correlated to HBeAg seroconversion, with P value as 0.003 (Table 1) . According to ROC curve, supposed AUC as 0.705 and P value as 0.042, the PPV, NPV, sensitivity and specificity of HBeAg level as 61 at 12 week were 0.361, 0.862, 0.765 and 0.521, respectively. Supposed AUC as 0.828 and P value as 0.001, the PPV, NPV, sensitivity and specificity of HBeAg level as 15 at 24 week were 0.452, 0.912, 0.824 and 0.646, respectively. The HBeAg level (s/co) and decreased degree (percentage) at 12 week and 24 week were significant related to HBeAg seroconversion (Table 2) . Conclusion HBeAg level at baseline and at 12th and 24th week and its decreased degree (percentage) during the treatment course could be used as predictive factor for HBeAg seroconversion. Background: It is well documented that perinatal transmission is the major cause of chronic HBV infection in China. The aim of this study was to evaluate the efficacy of interruption of HBV intrauterine infection with hepatitis B immunoglobulin (HBIG) in pregnant women with HBeAg positive. Methods:: A prospective randomized controlled trial was adopted. Each subject in the trial group (28 cases) was given 200 IU HBIG intramuscularly every 4 weeks from 28-week of gestation, while each subject in the control group (24 cases) received placebo in the same way. The cord blood of newborns were collected for detecting HBsAg, HBeAg and HBV-DNA. Results: For newborns, HBeAg positive rate in trial group was 21.4%(6/28).HBeAg positive rate in control group was 79.2%(19/24). There was significant difference in HBeAg positive rate of newborns between the two groups( P < 0.01, RR = 0.27). HBV-DNA positive rate in trial group was 25%(7/28). HBV-DNA positive rate in control group was 83.3%(20/24). There was significant difference in HBV-DNA positive rate of newborns between the two groups( P < 0.01, RR = 0.30). HBV-DNA load of 7 cases of newborns in trial group was lower than that of their mothers(T = 28,P = 0.02). There was no significant difference in HBV-DNA load between women and their newborns after delivery in control group (T = 81.5,P > 0.1). Conclusion: It is effective and safe to prevent HBV intrauterine infection with HBIG from the 28(th) wk in pregnant women with HBeAg positive. ), especially, the cirrhosis and HCC cases obviously more in both HBeAg and anti-HBe patients are negative than HBeAg-negative but anti-HBe positive patients (.36.7% vs 26.7%; 7.9%vs5.5%, p ) .The prevale nce of pre-core G1896A mutate have no significant difference regardless of HBV serum marker status or the state of illness. Conclusion: Recent 5 years the HBeAg-nagative chronic hepatitis B patients are gradually increasing in Yunnan province. While the HBeAg disappear but no anti-HBe serum transfer, and the virus still active replication -It may be a crucial phase determined the diseases outcome, which should be pay more attention by physicians. The clinical significant of pre-core G1896A mutate remain unknow.